XY Capital Ltd increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 432.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 765,137 shares of the company's stock after buying an additional 621,440 shares during the period. Takeda Pharmaceutical accounts for 6.4% of XY Capital Ltd's investment portfolio, making the stock its 3rd biggest position. XY Capital Ltd's holdings in Takeda Pharmaceutical were worth $10,919,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its position in shares of Takeda Pharmaceutical by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 143,115 shares of the company's stock valued at $2,359,000 after acquiring an additional 616 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Takeda Pharmaceutical by 28.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,976 shares of the company's stock valued at $46,000 after purchasing an additional 663 shares during the period. Contravisory Investment Management Inc. grew its position in shares of Takeda Pharmaceutical by 6.8% during the 3rd quarter. Contravisory Investment Management Inc. now owns 11,006 shares of the company's stock valued at $170,000 after purchasing an additional 705 shares in the last quarter. BNP Paribas Arbitrage SNC increased its holdings in shares of Takeda Pharmaceutical by 37.5% in the second quarter. BNP Paribas Arbitrage SNC now owns 2,781 shares of the company's stock worth $44,000 after purchasing an additional 759 shares during the period. Finally, Sage Rhino Capital LLC raised its position in shares of Takeda Pharmaceutical by 7.6% in the third quarter. Sage Rhino Capital LLC now owns 11,751 shares of the company's stock worth $182,000 after buying an additional 831 shares in the last quarter. 9.17% of the stock is owned by institutional investors.
Takeda Pharmaceutical Price Performance
Takeda Pharmaceutical stock traded down $0.04 during midday trading on Thursday, hitting $13.49. 1,783,265 shares of the company's stock were exchanged, compared to its average volume of 1,834,185. The stock has a 50-day moving average price of $14.41 and a two-hundred day moving average price of $14.46. Takeda Pharmaceutical Company Limited has a 52-week low of $13.19 and a 52-week high of $17.15. The company has a market cap of $42.68 billion, a P/E ratio of 20.43, a PEG ratio of 3.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.55 and a current ratio of 1.06.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The company had revenue of $7.52 billion for the quarter. On average, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current year.
Insider Activity
In related news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the company's stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total value of $29,999,994.30. Following the completion of the transaction, the insider now directly owns 3,755,583 shares in the company, valued at $30,420,222.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.04% of the company's stock.
Takeda Pharmaceutical Company Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
